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Objective: The aim of the current study was to identify molecular markers for articular cartilage (AC) that
can be used as tools for the quality control of tissue engineered (TE) cartilage.
Design: A genome-wide expression analysis was performed using RNA isolated from articular and growth
plate (GP) cartilage, both extracted from the knee joints of 6 weeks old minipigs. After conﬁrming the
speciﬁc expression for selected genes by RT-PCR, these were used as molecular markers for the quality
control of TE cartilage.
Results: Albeit several known chondrocyte markers were expressed to a similar extent in articular and GP
cartilage, our genome-wide expression analysis led us to identify genes being selectively expressed in
either GP or articular chondrocytes. These ﬁndings led us to perform a RT-PCR expression analysis for the
corresponding genes to demonstrate the absence of GP-speciﬁc markers in TE cartilage, while common
or AC markers were expressed.
Conclusions: Taken together, these results provide important novel insights into chondrocyte biology in
general and AC in particular. In addition, it is reasonable to speculate, that some of the identiﬁed genes
play distinct roles in the regulation of articular chondrocyte differentiation and/or function, thereby
raising the possibility that they may serve as targets for non-operative therapies of osteoarthritis (OA).
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is one of the most common predictors of
health, affectingmore than 100million individuals worldwide1. The
major problem in the treatment of OA is that articular cartilage (AC)
defects heal very poorly, which is a consequence of a low regen-
erative capacity of articular chondrocytes. This explains why
surgical interventions often become inevitable since no existing
medication substantially promotes the healing process2.
One tissue engineering approach of hallmark clinical impor-
tance is the implantation of autologous chondrocytes (ACI)3. ACIMichael Amling, Department
Center Hamburg-Eppendorf,
741056373.
Amling).
s Research Society International. Phas become a well-established and accepted surgical procedure for
the treatment of cartilage defects of the knee joint4,5. However, the
implantation of ACI is associated with typical complications6, and
in numerous cases in vitro-expanded and in vivo-implanted chon-
drocytes stimulate the formation of ﬁbrocartilagenous replacement
tissue instead of durable hyaline cartilage7. One possible explana-
tion for these complications lies in the paucity of knowledge con-
cerning the molecular regulation of articular chondrocyte
differentiation and function. In fact, although it is commonly
accepted that there are functional differences between growth
plate (GP) and articular chondrocytes, the quality of tissue engi-
neered (TE) cartilage is mostly controlled through the determina-
tion of glycosaminoglycan (GAG) content or type-II-collagen
production, and not by an expression analysis for speciﬁc molecular
markers.
A second and very promising surgical intervention for the repair
of AC defects is the implantation of autologous osteochondral
cylinders. This technique has been shown to provide superiorublished by Elsevier Ltd. All rights reserved.
Table I
Primers used for RT-PCR expression analysis
COL2A1 Forward-Primer: 50-GGCCTCCCCGGAACTC-30
Reverse-Primer: 50-CCTCTTCCGCCGTCTTTC-30
COMP Forward-Primer: 50-GGATGCCTGTGACAACTGTC-30
Reverse-Primer: 50-AAGGCCCTGAAGTCGGTGAG-30
COL10A1 Forward-Primer: 50-GCTCCCATCCCCTTTGATAAGA-30
Reverse-Primer: 50-AGCCTGATCCAGGTAGCCTTTG-30
ALPL Forward-Primer: 50-TTCAGAGGAGCTGGCATGT-30
Reverse-Primer: 50-TGTCCCCAAGCTCAGTCCTAAC-30
PTH1R Forward-Primer: 50-AAGTCCAGTGCCAATGTCCAG-30
Reverse-Primer: 50-CTTTGGCGTCCATTACATCGT-30
ABI3BP Forward-Primer: 50-CCATCTGGACTGAAAGACCCTT-30
Reverse-Primer: 50-CCACAAACTGGCAGTGATCTTC-30
THBS4 Forward-Primer: 50-ATCCAGGCGATCGAAATTCTG-30
Reverse-Primer: 50-AGGTGTCCTATCGCTGGTTCCT-30
SIX1 Forward-Primer: 50-CCAGCGTCCGGTCAAATTTAGT-30
Reverse-Primer: 50-CCAGGTTGCCAGATTTGTTAC-30
COL14A1 Forward-Primer: 50-GTGGTTAAGGAGGACAAGCCCT-30
Reverse-Primer: 50-TGCTGTGTATCCCTTAGCTCCG-30
PPA2B Forward-Primer: 50-TGTGGTTACAGGTAGCCCTTT-30
Reverse-Primer: 50-GGCAGTTCTTGGTAGGTTCTGC-30
PTGS1 Forward-Primer: 50-TGGAAGGCCACCAGAAATTCT-30
Reverse-Primer: 50- GGTGGTCTTGCTTGGTGTTCA -30
ESP8 Forward-Primer: 50-CCTGCCTCCAATCAAGATCAA-30
Reverse-Primer: 50-GAAATGTACCGTGTCCACTTGC-30
SHISA3 Forward-Primer: 50-CGTTAACCACTGTACCACGACG-30
Reverse-Primer: 50-GAAATGTACCGTGTCCACTTGC-30
GDF6 Forward-Primer: 50-TTACTCCATCGCTGAGAAGCTG-30
Reverse-Primer: 50-TGTGCGAGAGATCGTCTAGTCC-30
GP38K Forward-Primer: 50-ACCGGCACCATGTAAGACATG-30
Reverse-Primer: 50-CAAGTCAGGCTTTGCAGAGGAT-30
GEM Forward-Primer: 50-GAGCGTGGTTGGTGTTCACAT-30
Reverse-Primer: 50-GGC AAT CCT AGC TCC ACG AAT-30
NFIA Forward-Primer: 50-ACCAGCTCAAAAAACCTGTGGA-30
Reverse-Primer: 50-TGTTGTGAAACGAAACACCCC-30
MAP2 Forward-Primer: 50-ATTCCAAGGTTCCAACATGCC-30
Reverse-Primer: 50-CCAGCCATTGAAGAAATGCCT-30
TMEM30B Forward-Primer: 50-GCGCGCATCCGCCAGGGCAA-30
Reverse-Primer: 50-AGACGACCAGCATGACAAAG-30
NF1-B3 Forward-Primer: 50-TATTCTTCCTCCAGCCCCATC-30
Reverse-Primer: 50-TGGACATTTGCCGGTAGGA-30
MMP1 Forward-Primer: 50-ACCCCAAGGACATCCACAGAT-30
Reverse-Primer: 50-CAACTTTGTTGCCAATCCCAG-30
HIST1H2AC Forward-Primer: 50-TTTCAGAGCCCCCCACTATTTC-30
Reverse-Primer: 50-CAGGTGCAGGATCAGTCAATGA-30
OSX Forward-Primer: 50-CGACTGCCCCAACTGCCAGG-30
Reverse-Primer: 50-TGCCGTACACCTTGCCGC-30
RUNX2 Forward-Primer: 50-TGCCTCATCCCTGCCTCTGTGT-30
Reverse-Primer: 50-TGTGGGGCTGCTCAGGAGGG-30
GAPDH Forward-Primer: 50-CTTCGTCAAGCTCATTTCCTGG-30
Reverse-Primer: 50-AGTCAGGAGATGCTCGGTGTG-30
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Therefore, TE osteochondral implants appear to be highly prom-
ising alternatives and have shown to provide good results in animal
models11 and humans8. The requirements and components for
“lifelike” TE-cartilage are still elusive and up to this day sufﬁcient
chondrocyte-speciﬁc markers associated with successful engi-
neering of in vitro-cartilage have not been established.
Thus, the aim of our study was to perform a genome-wide
expression analysis comparing GP and articular chondrocytes, both
in vivo and in vitro, which led us to identify a set of genes being
speciﬁcally expressed in AC. Since these genes could not only serve
as molecular markers for the quality control of cartilage implants,
but also be of functional relevance for the regulation of articular
chondrocyte activities, we believe that our results may help to
optimize the therapeutical concepts for the treatment of AC lesions.
Materials and methods
Isolation of GP and articular chondrocytes
Bone-cartilage cylinders with an average length of 3 cm and
diameter of 0.5 cm were harvested from the medial and lateral
condyle of knee joints of 6 weeks old minipigs by using an electric
punch. Bone-cartilage cylinders were separated in articular and
GP cartilage and bone under the dissecting microscope with the
help of a scalpel and a forceps. Primary chondrocytes were iso-
lated from articular and GP cartilage by using collagenase type Ia
(SigmaeAldrich, Germany) solution. Therefore cartilage was
digested in 0.2% (w/v) collagenase in DMEM/Hams’F12
(PAA, Germany) for 4e5 h at 37C on a shaker and cultivated with
DMEM/Ham’F12 supplemented with 10% (v/v) FBS (Lonza,
Germany), 100 mg/mL Sodium pyruvate (SigmaeAldrich,
Germany), 100 U/mL penicillin (Invitrogen, Germany), 100 mg/mL
streptomycin (Invitrogen, Germany). Chondrocytes were seeded
in high density for monolayer (2106 cells/6-well-plate) and
cultured at 37C under an atmosphere of 5% (v/v) O2 and 5% (v/v)
CO2.
Histology of biopsies
For non-decalciﬁed histology bone-cartilage cylinders were
ﬁxed in formaldehyde (4% (v/v) in PBS). After dehydrating and
embedding inmethylmethacrylate, sections of 4 mmwere cut in the
sagittal plane on a Microtec rotation microtome (Techno-Med,
Germany). For Safranin-O staining sections were dehydrated,
stained in Safranin-O (3% (v/v) aqua dest.), afterwards washed in
acetic acid (1% (v/v) in aqua dest.) and submerged in Fast Green
solution (0.2% (w/v) in aqua dest.).
Expression analysis
Total RNAwas extracted from articular and GP cartilage of bone-
cartilage cylinders and cultured chondrocytes using the TRIzol
reagent (Invitrogen, Germany) followed by further puriﬁcation
using the RNeasy Mini Kit (Qiagen, Germany) according to the
manufacturer’s instructions. RNA was also isolated from various
tissues of 6 weeks old minipigs, as well as from TE-cartilage. For
microarray expression analysis Affymetrix porcine U74v2 Gene
Chips containing 24.000 genes and expressed sequence tags (ESTs)
were used. The targets for Affymetrix DNAmicroarray analysis were
prepared as described by themanufacturer. The amount of total RNA
used for the cDNA synthesis was 15 mg for each reaction. Gene Chip
microarrays were hybridized with the targets for 16 h at 45C,
washed and stained using the Affymetrix Fluidics Station according
to theGene Chip Expression Analysis TechnicalManual.Microarrayswere scanned with the Affymetrix Gene Chip Scanner 7G and the
signals were processed using the Gene Chip expression analysis
algorithm (Affymetrix, USA). To compare samples and experiments,
the trimmed mean signal of each array was scaled to a target
intensity of 100. Absolute and comparison analyseswere performed
with Affymetrix MAS 5.0 and GCOS 1.4 software using default
parameters. Annotations were further analyzed with interactive
query analysis at www.affymetrix.com. All expression data have
been submitted to the GEO archive (accession number: GSE23492).
To independently conﬁrm the hybridization data, we performed
RT-PCR expression analysis using samples from two different
animals. Therefore the isolated RNA from native material and
cultured chondrocytes was reverse transcribed using the Cloned
AMV First-Strand cDNA synthesis Kit (Invitrogen, Germany)
according to the manufacturer’s instructions. The resulting cDNA
was used for a PCR reaction with gene-speciﬁc primers (Table I).
The PCR products were separated on a 1.5% (w/v) agarose gel and
visualized by ethidium bromide staining.
Quantitative RT-PCR analysis was performed using a StepOne-
Plus system, predesigned TaqMan gene expression assays, and
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expression of ACAN, COL2A1, COL10A1, and GAPDH as an internal
control. THBS4 expression was analyzed by Fast SYBR Green Master
Mix (Applied Biosystems, USA). The standard curve proﬁles of
THBS4 and GAPDH (internal control) were generated by the Step
OnePlus software. Relative quantiﬁcationwas performed according
to the DDCT method, and results were expressed in the linear form
using the formula 2ΔΔCT for both RT-PCR assays.
Generation of TE-cartilage
Chondrocytes were isolated from the knee joint (femur) of
a 5-month-old domestic pig by using hyaluronidase type-III solu-
tion (SigmaeAldrich, Germany), trypsin (Roth, Germany) and
collagenase type Ia solution (SigmaeAldrich, Germany).
Cartilage-carrier-constructs were generated according to
a concept described previously12,13. Therefore isolated chon-
drocytes were expanded until passage 3. Proliferation of the cells
was performed in DMEM (PAA, Germany) supplemented with 10%
(v/v) FBS (PAA, Germany), 100 U/mL penicillin, 100 mg/mL strepto-
mycin (PAA, Germany), 25 mM HEPES (Roth, Germany) and 10 ng/
mL rhFGF-b (CellConcepts, Germany)14. Chondrocytes were then
trypsinated and sedimented onto a solid calcium phosphate carrier
(Sponceram HA, Zellwerk, Germany) to form a cell layer. To
initiate cell proliferationwithin 2 weeks of cultivation, the medium
mentioned abovewas used. Simultaneously, chondrocytes from the
same preculture were immobilized in alginate beads for 2 weeks
for re-differentiation and production of cartilage matrix.
After recovering cells from the gel, cartilage constructs were
prepared. Re-differentiated cells were centrifuged onto each cell
coated carrier, located in a special device12. For the preparation of
cartilage constructs without using any carrier, cells harvested from
alginate culture were centrifuged in a tube. After 2 days constructs
(sameprocedure for bothmethods)were transferred to12-well-plates
and cultivated for 3 weeks altogether in a high-density cell culture.
During cultivation of alginate beads and cartilage-carrier-
constructs, DMEM supplemented with 10% (v/v) porcine serum (PS,
Gibco, Germany), penicillin/streptomycin (100 U/mL penicillin and
100 mg/mL streptomycin, PAA, Germany), 25 mM HEPES, 0.28 mM
L-ascorbic acid 2-phosphate and 1 mM cysteine (SigmaeAldrich,
Germany) was used. Furthermore, during re-differentiation in
alginate gel 100 ng/mL rhIGF-I (CellConcepts, Germany) and 10 ng/
mL rhTGF-b1 (CellConcepts, Germany) were added to the
medium15. All cultivations were performed at 37C under an
atmosphere of 5% (v/v) O2 and 5% (v/v) CO2.
Histological analysis of TE-cartilage
For histological analysis of TE-cartilage samples were ﬁxed in
formaldehyde (4% (v/v) in PBS), dehydrated and embedded in
methylmethacrylate (Merck, Germany). Sections of 4 mm thickness
were cut in the sagittal plane on a Microtec rotation microtome
(Techno-Med, Germany) and stained by Toluidine blue (1% (w/v) in
aqua dest.) and Safranin-O. Immunohistochemistry was performed
on decalciﬁed sections using a monoclonal antibody against human
type-II-collagen (1:100, Acris, Germany). A biotinylated secondary
antibody against mouse-IgG (Dako, Denmark) was used, followed
by a streptavidin (Dako, Denmark) and horseradish peroxidase
(Dako, Denmark). Peroxidase activity was detected using dia-
minobenzidine (Dako, Denmark) as chromogenic substrate.
Biochemical analysis and biomechanical parameters of TE-cartilage
To quantify biochemical properties of cartilage constructs, GAG
content was determined according to Buschmann et al.15. Thegenerated tissue was digested with papain solution (Roche,
Germany). The GAG content was thenmeasured photometrically by
staining with 1,9-dimethylmethylene blue chloride (Serva,
Germany). For measuring the height and the Young’s Modulus,
a high-precision material testing equipment (Zwicki 1120, Zwick,
Germany) was used. The Young’s Modulus was determined by
stepwise stress-relaxation tests according to Korhonen et al.16. The
criterion for relaxation was a relaxation rate less than 0.002 N/min.
The Young’s Modulus was calculated from resulting stressestrain
curve. Results are shown as means and error bars represent 95%
conﬁdence interval. For statistical analysis (Student’s t-Test) the
software NCSS 97 was used.
Results
Isolation and molecular proﬁling of GP and articular chondrocytes
The histological analysis of the harvested bone-cartilage cylin-
ders using Safranin-O staining showed intact articular and GP
cartilage, separated by epihyseal bone [Fig. 1(A)]. Since this allowed
a clear discrimination between both types of cartilage, we were not
only able to isolate RNA from the corresponding native tissues, but
also to isolate articular and GP chondrocytes. These were then
cultured for 10 and 20 days, before we isolated RNA that was used
for Affymetrix Gene Chip hybridization, together with the RNA
from the native tissues. This allowed the simultaneous quantiﬁca-
tion of mRNA expression for approximately 20.000 genes in both
types of cartilage, both in vivo (native tissues) and in vitro (cultured
cells).
Using this approach we ﬁrst observed that common chon-
drocyte markers, such as COL2A1 (encoding a1-type-II-collagen),
ACAN (encoding Aggrecan) and COMP (encoding Cartilage oligo-
meric matrix protein) were expressed at similar levels in articular
and GP cartilage, both in vivo and in vitro [Fig. 1(B)]. In contrast,
genes, which are known to regulate differentiation and function of
hypertrophic chondrocytes, such as ALPL (encoding Tissue-non-
speciﬁc alkaline phosphatase), COL10A1 (encoding a1-type-X-
collagen) and PTH1R (encoding the PTH/PTHrP receptor) were
selectively expressed in GP chondrocytes and this molecular
difference to articular chondrocytes was still present after 10 days
of in vitro culture [Fig. 1(C)]. Most importantly however, we were
also able to identify genes, such as ABI3BP (encoding a Abl inter-
actor family member), THBS4 (encoding Thrombospondin-4) and
SIX1 (encoding a sine-oculis-related homeobox transcription
factor) that were only expressed in articular chondrocytes, both in
vivo and in vitro [Fig. 1(D)]. Taken together, these initial data did not
only demonstrate the success of the chosen approach, but also
provided evidence for a cell-autonomous molecular difference
between GP and articular chondrocytes that persists under tissue
culture conditions.
Identiﬁcation of speciﬁc GP and AC markers
Since it is possible to sort all genes present on the Gene Chips
according to their signal log ratios (SLR) of differential expression
between articular and GP chondrocytes, we went on to deﬁne 34
markers of GP chondrocytes and 19 markers of articular chon-
drocytes, which are listed in Tables II and III, respectively. The
chosen inclusion criteria were that all of these genes displayed
a SLR below 2.0 (higher expression in GP chondrocytes) or above
2.0 (higher expression in articular chondrocytes), both in vivo and
in vitro (day 10 of differentiation), and that the Affymetrix signal
intensity was higher than 50 at least in one type of cartilage.
Most importantly, this type of analysis revealed that the most
speciﬁc marker of hypertrophic chondrocytes, COL10A1, displayed
Fig. 1. Strategy for the identiﬁcationofAC-speciﬁcmarkers. (A)Gross appearance (left) of a bone-cartilage cylinderharvested fromtheknee jointof a 6weeksoldminipig (thedotted lines
indicateAC andGP cartilage), and Safranin-O staining of non-decalciﬁed sections (middle), showing red stainingof cartilage. The right panels show the similarmorphological appearance
of articular and GP chondrocytes after 10 days of tissue culture. (B) Affymetrix signal intensities for COL2A1, ACAN and COMP showing expression in both types of cartilage, in vivo and
invitro. (C)Affymetrix signal intensities forALPL,COL10A1andPTH1R showingspeciﬁc expression inGPchondrocytes. (D)Affymetrix signal intensities forABI3BP, THBS4 and SIX1 showing
speciﬁc expression articular chondrocytes. (BeD) For each sample cartilage was harvested from both knee joints of two individual animals and pooled before preparation.
Table II
Genes with increased expression in GP cartilage. Given are the Affymetrix signal
intensities and the SLR for GP and AC in native tissues (in vivo) and cultured cells
(in vitro) at day 10 and day 20 of differentiation
In vivo In vitro In vitro
d10 d20
Gene GP AC SLR GP AC SLR GP AC SLR
COL10A1 1114 4 7.8 2374 26 6.2 1654 30 5.1
SLC38A4 165 0 7.7 297 52 2.7 96 17 2.2
IBSP 10642 53 7.5 14033 203 5.3 15675 5957 1.3
LEF1 2407 28 7.2 1140 178 2.5 2031 175 3.1
DIO2 2589 16 6.8 4551 126 5.3 829 278 1.7
GPR133 133 2 6.5 363 20 4.3 2324 21 3.4
ALPL 1521 24 6.4 3056 29 6.7 2286 90 4.4
FLRT3 85 1 6.2 183 18 3.0 50 4 2.5
EFHD1 1523 34 5.6 2851 182 4.2 1657 926 0.9
CA2 353 9 5.2 251 11 3.8 236 14 3.8
ANGPT1 1624 48 5.0 1338 79 3.9 704 216 1.8
PTH1R 3430 135 4.8 4864 503 3.3 3352 1118 1.4
ENPP2 3359 134 4.6 2954 292 3.3 1412 443 1.6
A2M 716 11 4.6 668 40 4.0 389 67 2.8
ADAMTS1 578 20 4.3 678 30 4.3 136 192 0.5
BAMBI 602 38 4.1 1930 402 2.4 416 299 0.4
LRRC1 261 11 4.1 266 40 2.3 230 99 1.2
OVOL1 105 5 4.0 87 6 2.9 190 62 1.9
S1PR3 53 3 3.7 5 10 2.3 234 57 2.3
GPR120 285 24 3.2 716 37 4.3 92 40 1.0
REEP1 1096 117 3.1 786 133 2.4 1051 139 2.6
VAV3 239 30 3.0 359 37 2.2 208 31 2.5
SPARCL1 696 64 2.9 2977 409 2.8 4635 3975 0.3
F13A1 6196 1277 2.9 8127 661 3.6 8943 3060 2.1
WNT5A 132 24 2.8 176 32 3.1 99 87 0.4
CAPNS1 995 117 2.7 2128 124 4.1 2502 530 2.3
EPHA3 115 19 2.7 1178 154 3.2 891 243 2.2
TMTC1 590 83 2.7 559 143 2.1 271 497 0,7
SHAS2 1029 156 2.7 1183 206 2.1 501 201 1.5
GRB14 91 12 2.6 187 9 3.7 21 1 4.5
MTSS1 228 39 2.5 320 40 2.4 311 192 0.5
PART1 87 17 2.4 164 40 2.0 271 497 0.7
MAEF2C 799 153 2.3 1462 265 2.2 690 564 0.6
GRIP1 236 43 2.1 324 41 2.1 151 93 0.7
Table III
Genes with increased expression in AC. Given are the Affymetrix signal intensities
and the SLR for GP and AC in native tissues (in vivo) and cultured cells (in vitro) at day
10 and day 20 of differentiation.
In vivo In vitro In vitro
d10 d20
Gene GP AC SLR GP AC SLR GP AC SLR
ABI3BP 2 475 7.7 10 579 6.0 26 665 4.1
THBS4 8 1986 6.9 13 856 4.6 16 353 4.4
SIX1 223 3717 4.1 139 961 2.8 217 2284 3.3
COL14A1 90 1177 4.0 49 1628 4.7 104 3073 4.9
PPAP2B 433 7803 3.9 201 656 2.0 260 1616 2.7
PTGS1 199 1577 3.0 76 810 3.6 73 123 0.7
TMEM30B 32 95 2.9 52 137 2.1 5 262 5.4
ESP8 333 2795 2.9 241 1351 2.0 234 896 1.9
NOV 23 70 2.8 75 1542 4.4 5918 12564 1.1
SHISA3 21 244 2.7 11 179 4.2 2 629 8.5
GAS1 29 129 2.7 22 709 4.3 57 723 3.4
GDF6 19 94 2.6 37 123 2.3 56 326 2.6
GP38K 2983 15448 2.5 81 1193 3.9 89 1395 4.2
GEM 1333 6431 2.4 238 1365 2.5 203 1278 2.7
NF1-B3 215 1109 2.4 113 442 2.0 37 316 3.1
NFIA 133 572 2.4 118 630 2.7 21 387 3.6
MMP1 160 806 2.4 29 149 2.1 124 80 1.0
HIST1H2AC 40 222 2.1 71 459 2.3 38 55 0.8
MAP2 84 315 2.0 94 453 2.4 135 409 1.7
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conﬁrming again the success of the chosen approach (Table II). This
implies that at least some of the other genes with increased
expression in GP chondrocytes might be functionally relevant for
their differentiation and function. Since the primary focus of our
study was however to identify genes being selectively expressed in
articular chondrocytes, the results presented in Table III are even
more relevant. Here we observed the highest SLR for the gene
ABI3BP, which encodes a cytoplasmatic adaptor protein inducing
cellular senescence in cancer cells. Another differentially expressed
gene with a potential importance for articular chondrocyte differ-
entiation was GDF6, encoding a growth factor, whose inactivation
in mice causes defects of cartilage formation within the joints17. To
address the question, for how long the molecular differences
between GP and articular chondrocytes would persist in tissue
culture, we have further compared primary cells at day 20 of
differentiation, where we observed that the majority of the iden-
tiﬁed molecular markers were still differentially expressed.
Based on these results we reasoned that we could use at least
some of the genes listed in Table III as markers for the quality
control of TE-cartilage. For that purpose, we ﬁrst performed RT-PCR
expression analysis to conﬁrm the results obtained by Affymetrix
Gene Chip hybridization. Here we observed that in contrast to
common cartilagemarkers and GP-speciﬁc markers, the expression
of most of the genes listed in Table III (13 out of 19) was much
higher in AC (Fig. 2), while the expression of the others was not
detectable in either cartilage by RT-PCR (Supplemental Fig. 1).
Another important observationwas that THBS4 and SIX1 expressionwas barely detectable in several other tissues, thus implying
a potential relevance for chondrocyte differentiation and function.
Histological, functional and molecular analysis of TE-cartilage
TE-cartilage was either generated without a carrier substance or
on a hydroxyapatite (HA)-carrier [Fig. 3(A)]. The histological anal-
ysis of both types of TE-cartilage showed a well-organized extra-
cellular matrix with regularly shaped chondrocytes [Fig. 3(B)].
Safranin-O staining additionally revealed that the proteoglycan
content appeared to be higher in TE-cartilage grown on a HA-
carrier, and a similar observation was made by immunohisto-
chemistry using an antibody against type-II-collagen [Fig. 3(C)].
Inconsistent with these histological ﬁndings, we did neither
observe differences in the GAG content, nor did biomechanical
testing reveal statistically signiﬁcant differences in the Young’s
Modulus, when TE-cartilage grown on a HA-carrier was compared
to TE-cartilage grown without a carrier [Fig. 3(D)].
Since our expression analysis has provided the possibility for
a molecular control of TE-cartilage, we went on by analyzing gene
expression in four samples of TE-cartilage by RT-PCR. Here we found
that COL2A1 was expressed in all samples, whereas markers for GP
cartilage were not expressed [Fig. 4(A)]. Most importantly however,
we observed a high expression of ABI3BP, SIX1 and GDF6 in the two
TE-cartilage samples grown on a carrier, while their expression in
carrier-free TE-cartilage was lower. Interestingly, THBS4 expression
was only observed in native AC, but not in TE-cartilage, thereby
demonstrating that the culture conditions still need tobe improved in
order to obtain a quality, which is comparable to the in vivo situation.
Given the potential relevance of these ﬁndings for an efﬁcient
quality control of TE-cartilage in the future, we ﬁnally performed an
initial qRT-PCR expression analysis, where we compared the
expression of COL2A1, ACAN, COL10A1 and THBS4 in native and TE-
cartilage. Here we found that the expression of ACAN and COL2A1
was reduced by more than 50% in TE-cartilage compared to native
AC, while COL10A1 and THBS4were barely expressed in TE-cartilage
[Fig. 4(B)]. Taken together, these data underscore the importance of
a molecular control of TE-cartilage, since ideally there should be
a similar expression level of all relevant markers, when compared
to the native tissue.
Fig. 3. Histological analysis of TE-cartilage. (A) Gross image of TE-cartilage grown
without () or with (þ) a HA-carrier. (B) Toluidine blue (top) and Safranin-0 (bottom)
staining of TE-cartilage. (C) Immunohistochemistry with an antibody against type-II-
collagen. (D) GAG content and biomechanical stability (Young’s Modulus) of TE-
cartilage. Values are presented as means of three independent preparations. Error bars
represent 95% conﬁdence interval. No statistical differences were noted between the
two types of TE-cartilage.
Fig. 2. Tissue-speciﬁc expression of molecular cartilage markers. RT-PCR expression
analysis for the indicated genes in various porcine tissues, including GP and AC. Note
that the molecular markers listed in Table III display higher expression in AC compared
to GP cartilage. To conﬁrm the results of the Affymetrix Gene Chip hybridization
cartilage was harvested from knee joints of two additional animals.
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Fig. 4. Molecular analysis of TE-cartilage. (A) RT-PCR expression analysis of the indi-
cated genes in native GP and AC, compared to four TE-cartilage preparations without
() or with (þ) carrier. (B) Quantitative RT-PCR expression analysis for the indicated
genes in native GP and AC, compared to TE-cartilage grownwith a HA-carrier (TE). Bars
represent mean of three independent preparations for native AC and TE-cartilage (TE),
and one preparation for native GP cartilage. Error bars show the 95% conﬁdence
interval about the mean position. There were no statistical differences detectable
between samples isolated from AC and TE-cartilage with carrier.
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Given the fact that the therapeutical options for the treatment of
OA are still limited, it is of hallmark clinical relevance to understand
the molecular mechanisms regulating articular chondrocyte
differentiation and function. Even though extensive research efforts
have been made to identify such genes and molecular markers,
little is known about the components needed to successfully create
durable in vitro AC resembling native human cartilage18e20. In this
regard, it was an important ﬁrst step that we were able to identify
a set of genes being expressed in articular chondrocytes, but not inchondrocytes derived from the GP. Interestingly, and this was not
expected a priori, the molecular differences between GP and
articular chondrocytes were still detectable after 10 and 20 days of
tissue culture, which is a very valuable information for the gener-
ation of TE-cartilage. Most importantly however, our results have
provided the possibility for an efﬁcient quality control of TE-carti-
lage, since the sole histological analysis has obvious limitations.
In this regard, we believe that it is rather a strength than
a weakness of our manuscript, that we were not able to detect
expression of THBS4 in the four analyzed TE-cartilage samples,
unlike it was the case for other molecular markers of AC. Also,
typical markers of bone such as Osterix (OSX) and RUNX2 were not
detectable in TE-cartilage by RT-PCR (Supplemental Fig. 2). In fact,
this ﬁnding underscores, why it is important to compare gene
expression in TE-cartilage to the native tissue, since it is reasonable
to speculate that at least some of the identiﬁed molecular markers
are also functionally relevant for tissue integrity. Moreover, by
monitoring gene expression in TE-cartilage, it will be possible to
optimize the culture conditions, for instance by supplementing the
medium with additional growth factors, such as GDF6.
In our study we have identiﬁed at least 13 genes that are
expressed at higher levels in articular compared to GP cartilage and
that might be used for the quality control of TE-cartilage in future
experiments. Since we have used a porcine model however, there is
a likely possibility that we did not identify all putative articular
chondrocyte markers, which is readily explained by the fact that
the porcine Gene Chips do not represent the same number of genes
yet as the human or murine Gene Chips. In this regard, it is
important to state that a similar approach has previously been
performed with GP and AC from wildtype mice21. To overcome the
limited amount of extractable RNA from the corresponding mouse
tissues, the authors have used laser capture microdissection and
ampliﬁed the RNA by in vitro transcription, before performing
Affymetrix Gene Chip hybridization. This has lead to the identiﬁ-
cation of 27 genes with at least 10-fold higher expression in artic-
ular chondrocytes, four of them (SIX1, PPAP2B, COL14A1 and GAS1)
also identiﬁed by us, while ﬁve others (IGFBP5, TMEM30B, ANK,NFIB
and SOCS3) displayed a more than two-fold increase in native AC in
our experiments (data not shown). Althoughwe can only speculate,
why these authors did not identify other genes, such as ABI3BP or
THBS4, in their comparative analysis, it is important to state that 11
of the 27 genes listed by Yamane et al. were not presented on the
porcine Gene Chips, one of them being PRG4 (encoding Lubricin,
also known as Superﬁcial zone protein), which has been long
considered as a speciﬁc marker of articular condrocytes22. Given
this argumentation, it will be important to use both sets of data in
order to screen for ideal markers for the quality control of TE-
cartilage in the future.
Regardless of this issue however, we further believe that the
genes identiﬁed in our study are not only excellent markers for the
quality control of TE-cartilage, but also some of themmay even serve
as promising targets for therapeutical approaches. In this regard, it
will be important to study the functional relevance of candidate
genes for articular chondrocyte differentiation and for the integrity
of the produced extracellular matrix. Although, it might be worth-
while to do this systemically for all of the identiﬁedmarkers in future
experiments, the genes ABI3BP, THBS4, SIX1 and GDF6 appear to be
particularly interesting, either based on their expression pattern, or
given the previous knowledge published by others.
In fact, while GDF6 is already known to play a key role in cartilage
formation and joint development17, ABI3BP has been described as
a senescence-inducing gene in different cell types23. Thus, given the
fact that articular chondrocytes are embedded into their own extra-
cellularmatrix for long periods, they appear to be in a state of cellular
senescence, and ABI3BP may be one of the factors promoting this
T.N. Hissnauer et al. / Osteoarthritis and Cartilage 18 (2010) 1630e1638 1637state. Cellular senescence has been associated with OA, but despite
great research efforts little is known about speciﬁc mechanisms and
genes initiating senescence in chondrocytes24,25. It has additionally
been suggested that progressive cell senescence might decrease the
ability of chondrocytes to maintain and restore AC24. Albeit inter-
esting, it is unlikely that such a potential role of ABI3BP will even-
tually result in the development of a therapeutic agent stimulating
articular chondrocyte regeneration, since ABI3BP is expressed in
many other tissues and since it has an intracellular localization.
The same is true for SIX1, which encodes a homeobox tran-
scription factor located in the nucleus26. That SIX1 has other func-
tions besides regulating chondrogenesis is well accepted, since
mutations within the SIX1 gene cause branchio-oto-renal
syndrome, being characterized by branchial and renal anomalies,
together with deafness and preauricular pits27,28. Likewise, Six1-
deﬁcient mice showed abnormal development of the inner ear,
nose, thymus, kidney and skeletal muscle and died immediately
after birth29. Affection of articular or GP cartilage was not reported,
since homozygous mutants were apnoeic and died immediately
after birth. A markedly reduced skeletal muscle mass of the trunk,
limbs, diaphragm and tongue was found. No observations
regarding AC were made. It is therefore not known, if these mice
were born with pathologically altered AC or if they might have
developed OA during lifetime.
In this regard, it will be most promising to study the role of the
extracellular matrix protein THBS4 for AC integrity in future
experiments. In fact, THBS4 showed the highest speciﬁcity for AC
expression in our RT-PCR screening, which is important, since the
other four members of the thrombospondin family were expressed
in both, GP and AC (data not shown). Moreover, while most of the
other thrombospondins, especially THBS1, THBS2 and COMP (also
known as THBS5), have been functionally studied extensively30,31,
there is nearly no published information so far concerning the
physiological role of THBS4. In this regard it will be useful to analyze
the skeletal phenotype of Thbs4-deﬁcient mice with a special focus
on AC thickness and regeneration.
Regardless of these functional studies however, our study has
provided novel options to control the quality of TE-cartilage. This is
of hallmark importance since information regarding the inﬂuence
of chondrocyte quality for the clinical outcome of tissue engi-
neering applications such as ACI or the implantation of TE grafts
remains is still very limited32. Since the approach in quality control
of chondrocytes presented in this study might eventually lead to
improved clinical results in OA, we believe that they are of imme-
diate clinical relevance.
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